Solid Tumor Clinical Trials in Seattle, Washington

7 studies are recruiting for solid tumor in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Research Center, Seattle, Washington

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

2. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

   This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Local Institution - 134, Seattle, Washington

   Locations

   25 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT05245500 on ClinicalTrials.gov

3. SMP-3124LP in Adults With Advanced Solid Tumors

   An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Washington, Seattle, Washington

   Locations

   12 in total

   Run by

   Sumitomo Pharma America, Inc.

   See if you can join NCT06526819 on ClinicalTrials.gov

4. A Study of 177Lu-FAP-2286 in Advanced Solid Tumors

   Fibroblast activation protein (FAP) is a cell surface protein that is highly expressed on the surface of cancer-associated fibroblasts (CAFs) present in the tumor microenvironment of most epithelial cancers, whereas limited expression of FAP is observed in normal tissues. In some cancers of mesench…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   41 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04939610 on ClinicalTrials.gov

5. A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors

   This is a Phase 1/2, open label, multiple cohort study to assess the safety and preliminary efficacy of SAR445877 as a monotherapy or in combination with other anticancer therapies for participants aged at least 18 years with advanced unresectable or metastatic solid tumors. The study will include …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center- Site Number : 8400010, Seattle, Washington

   Locations

   22 in total

   Run by

   Sanofi

   See if you can join NCT05584670 on ClinicalTrials.gov

6. Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

   This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.

   Stage

   Not phased

   Ages

   Up to 30

   Site

   Seattle Childrens Hospital, Seattle, Washington

   Locations

   6 in total

   Run by

   St. Jude Children's Research Hospital

   See if you can join NCT06579469 on ClinicalTrials.gov

7. VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors

   This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.

   Stage

   Phase 1

   Ages

   0 to 30

   Site

   Seattle Children's, Seattle, Washington

   Locations

   7 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT04796012 on ClinicalTrials.gov